Baird Financial Group Inc. Has $3.57 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Baird Financial Group Inc. trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,125 shares of the medical equipment provider’s stock after selling 12,857 shares during the period. Baird Financial Group Inc.’s holdings in Zimmer Biomet were worth $3,569,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ZBH. Hilltop National Bank bought a new stake in shares of Zimmer Biomet during the second quarter valued at approximately $42,000. True Wealth Design LLC lifted its holdings in shares of Zimmer Biomet by 875.0% in the 2nd quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 420 shares in the last quarter. Zions Bancorporation National Association UT acquired a new stake in Zimmer Biomet in the 1st quarter valued at $48,000. Brooklyn Investment Group increased its stake in Zimmer Biomet by 45.9% during the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 145 shares in the last quarter. Finally, FNY Investment Advisers LLC raised its holdings in Zimmer Biomet by 72.5% during the second quarter. FNY Investment Advisers LLC now owns 690 shares of the medical equipment provider’s stock worth $62,000 after buying an additional 290 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $93.18 on Thursday. The company has a market capitalization of $18.47 billion, a PE ratio of 23.06, a price-to-earnings-growth ratio of 2.43 and a beta of 0.61. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. Zimmer Biomet Holdings, Inc. has a 52-week low of $85.33 and a 52-week high of $114.44. The company has a 50-day simple moving average of $95.96 and a 200 day simple moving average of $96.74.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same period in the prior year, the firm earned $1.74 EPS. The company’s revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ZBH shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. Royal Bank Of Canada cut their target price on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, November 6th. Stifel Nicolaus set a $110.00 price target on Zimmer Biomet in a report on Wednesday, November 5th. Evercore ISI dropped their price objective on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 7th. Finally, Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and an average price target of $109.00.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.